In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Nephros, with a price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Robert Wasserman’s rating is based on Nephros’s impressive financial performance in the second quarter of 2025, where the company exceeded expectations with a significant increase in revenue and a shift to positive net income. The revenue growth was driven by strong programmatic sales and a substantial order in dialysis filtration, alongside an expansion in active user sites.
Additionally, Nephros has successfully launched new products and expanded its market reach beyond hospitals, contributing to its sales growth. The company also reported improved gross margins and a rise in adjusted EBITDA, strengthening its cash position with no long-term debt. These factors, combined with anticipated revenue growth, support the maintained Speculative Buy rating and a price target that suggests potential price appreciation.
In another report released on August 8, Maxim Group also maintained a Buy rating on the stock with a $6.00 price target.